Home / Market News / $INSP
benzinga Corporate Catalyst Impact 55/100 ● positive

Truist Securities Maintains Hold on Inspire Medical Systems, Raises Price Target to $78

Oct 14, 2026, 5:31 PM UTC · Primary ticker $INSP

Truist Securities analyst Richard Newitter has reiterated a 'Hold' rating on Inspire Medical Systems (INSP) and increased its price target from $62 to $78. This indicates a moderately positive outlook from the analyst, suggesting potential upside for the stock but not a strong buy recommendation.

Truist Securities analyst Richard Newitter maintained a 'Hold' rating on Inspire Medical Systems (INSP) but raised the price target from $62 to $78. This action signals a slightly more optimistic view on the company's future performance, as a higher price target typically implies an expectation of increased stock value. While the 'Hold' rating suggests the analyst doesn't see a compelling reason to aggressively buy or sell the stock at current levels, the increased price target could provide a short-term positive sentiment boost for INSP. Long-term implications depend on whether the company's fundamentals align with this revised valuation. Traders might see this as a moderate opportunity for short-term gains if the market reacts positively to the news, but the 'Hold' rating limits the potential for a significant rally.

$INSP positive Price target raised by analyst
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.